Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis

Table 2 Base case results

Strategies	Total costs (USD)	LYs	QALYs	Incremental costs (USD)	Incremental LYs	Incremental QALYs	ICER (USD/LY gained)	ICER (USD/QALY gained)
No screening	5757	17.23	10.44	-	-	-	-	-
ASAVLD	5472	17.69	10.60	− 285	0.47	0.17	Dominated^a	Dominated^a
Colonoscopy	4296	18.03	10.81	− 1176	0.34	0.21	Dominated^a	Dominated^a
Colonoscopy and ASAVLD	3679	18.43	10.93	− 617	0.40	0.12	Cost-saving	Cost-saving

ASAVLD, very low dose aspirin; ICER, incremental cost-effectiveness ratio; LYs, life-years; QALYs, quality-adjusted life years; USD, US dollar
^aDominated by combination of colonoscopy and ASAVLD

ISSN: 1471-230X